Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - thiopental sodium, quantity: 470 mg - injection, powder for - excipient ingredients: - ? as the sole anaesthetic agent for brief surgical procedures.,? induction of anaesthesia prior to the administration of other anaesthetic agents.,? short-term control of convulsive states.,? supplement to regional anaesthesia or low potency agents such as nitrous oxide.

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - acetylcysteine, quantity: 800 mg - solution - excipient ingredients: hydrochloric acid; water for injections; disodium edetate; sodium hydroxide - adjuvant therapy for patients with abnormal, viscid or inspissated mucous secretions in such conditions as: - chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung); - acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); - pulmonary complications of cystic fibrosis; - pulmonary complications associated with surgery; - post-traumatic chest conditions; - atelectasis due to mucus obstruction; - tracheostomy care; - anaesthesia. acetylcysteine may also be used as an adjunct to diagnostic bronchial studies (bronchograms, bronchospirometry and bronchial wedge catheterisation).

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - acetylcysteine, quantity: 2000 mg - solution - excipient ingredients: disodium edetate; sodium hydroxide; water for injections; hydrochloric acid - adjuvant therapy for patients with abnormal, viscid or inspissated mucous secretions in such conditions as: - chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung); - acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis); - pulmonary complications of cystic fibrosis; - pulmonary complications associated with surgery; - post-traumatic chest conditions; - atelectasis due to mucus obstruction; - tracheostomy care; - anaesthesia. acetylcysteine may also be used as an adjunct to diagnostic bronchial studies (bronchograms, bronchospirometry and bronchial wedge catheterisation).

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - cefepime -

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - cefepime -

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - cefepime -

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - piperacillin sodium, quantity: 4170 mg (equivalent: piperacillin, qty 4000 mg); tazobactam sodium, quantity: 536 mg (equivalent: tazobactam, qty 500 mg) - injection, powder for - excipient ingredients: - omegapharm piperacillin and tazobactam is indicated for the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the following conditions, - lower respiratory tract infections, - urinary tract infections (complicated and uncomplicated), - intra-abdominal infections, - skin and skin structure infections, - bacterial septicaemia, and, - gynaecological infections. children under the age of 12 years. in hospitalised children aged 2 to 12 years, omegapharm piperacillin and tazobactam is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years. . while omegapharm piperacillin and tazobactam is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin resistant organisms. appropriate culture and susceptibility tests sho

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - piperacillin sodium, quantity: 2085 mg (equivalent: piperacillin, qty 2000 mg); tazobactam sodium, quantity: 268 mg (equivalent: tazobactam, qty 250 mg) - injection, powder for - excipient ingredients: - omegapharm piperacillin and tazobactam is indicated for the treatment of serious bacterial infections caused by susceptible strains of beta-lactamase producing organisms in the following conditions, - lower respiratory tract infections, - urinary tract infections (complicated and uncomplicated), - intra-abdominal infections, - skin and skin structure infections, - bacterial septicaemia, and, - gynaecological infections. children under the age of 12 years. in hospitalised children aged 2 to 12 years, omegapharm piperacillin and tazobactam is indicated for the treatment of serious intra-abdominal infections. it has not been evaluated in this indication for paediatric patients below the age of 2 years. . while omegapharm piperacillin and tazobactam is indicated only for the conditions listed above, it may be used as a single agent in the treatment of mixed infections caused by piperacillin susceptible and beta-lactamase producing, piperacillin resistant organisms. appropriate culture and susceptibility tests sho

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - ceftazidime pentahydrate, quantity: 2349 mg (equivalent: ceftazidime, qty 2000 mg) - injection, powder for - excipient ingredients: sodium carbonate - omegapharm ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. . indications include the following.. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns.. respiratory tract. for example: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections. for example: otitis media, mastoiditis.. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones.. skin and soft tissue. . for e

Australia - English - Department of Health (Therapeutic Goods Administration)

omegapharm - ceftazidime pentahydrate, quantity: 1175 mg (equivalent: ceftazidime, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - omegapharm ceftazidime for injection is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. . indications include the following.. severe infections in general. for example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns.. respiratory tract. for example: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections. for example: otitis media, mastoiditis.. urinary tract. for example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones.. skin and soft tissue. . for e